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Introduction
Systemic cancer and ischemic stroke are both common condi-
tions, and are two of the most common causes of death among 
the elderly. The number of people living with cancer is increas-
ing, and the steadily increasing proportion of elderly people in 
the world is predicted to result in an increase of approximate-
ly 50% in new cancer cases over the next 20 years, with the 
number of new cases each year rising from 10.9 million in 2002 
to 16 million in 2020 (World Health Organization, Global ac-
tion against cancer, 2005). In addition, improvements in treat-
ment practice (cancer medicine) have the potential of improv-
ing survival by up to 15%. Therefore, the number of stroke patients 
with cancer is expected to rise with increases in the number of 
people living with cancer. Moreover, associations between can-
cer and stroke have been reported. Cerebrovascular disease oc-
curs commonly in cancer patients, with 15% of cancer patients 
experiencing a thromboembolic event during their clinical 
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BackgroundzzCancer and ischemic stroke are two of the most common causes of death among 
the elderly, and associations between them have been reported. However, the main pathomecha-
nisms of stroke in cancer patients are not well known, and can only be established based on accu-
rate knowledge of the characteristics of cancer-related strokes. We review herein recent studies 
concerning the clinical, laboratory, and radiological features of patients with cancer-related 
stroke.
Main ContentszzThis review covers the epidemiology, underlying mechanisms, and acute and 
preventive treatments for cancer-related stroke. First, the characteristics of stroke (clinical and ra-
diological features) and systemic cancer (type and extent) in patients with cancer-specific stroke 
are discussed. Second, the role of laboratory tests in the early identification of patients with can-
cer-specific stroke is discussed. Specifically, serum D-dimer levels (as a marker of a hypercoagu-
lable state) and embolic signals on transcranial Doppler (suggestive of embolic origin) may pro-
vide clues regarding changes in the levels of coagulopathy related to cancer and anticoagulation. 
Finally, strategies for stroke treatment in cancer patients are discussed, emphasizing the importance 
of preventive strategies (i.e., the use of anticoagulants) over acute revascularization therapy in can-
cer-related stroke.
ConclusionzzRecent studies have revealed that the characteristics of cancer-related stroke are 
distinct from those of conventional stroke. Our understanding of the characteristics of cancer-relat-
ed stroke is essential to the correct management of these patients. The studies presented in this re-
view highlight the importance of a personalized approach in treating stroke patients with cancer.
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course.
1 As a consequence, the proportion of patients who have 
cancer is expected to increase among stroke patients.
The treatment of stroke in cancer patients can be challenging, 
requiring the development of specific treatment strategies. Al-
though patients with systemic cancer usually have poor outcomes, 
their survival rate is increasing with the development of more 
effective cancer medicines. Early identification of stroke mech-
anisms may be important in cancer patients, because stroke mech-
anisms in cancer patients may differ from those in stroke patients 
without cancer. However, the mechanisms underlying stroke in 
patients with cancer are largely unknown.
2-4 The prevention and 
appropriate treatment of stroke in cancer patients require an ac-
curate understand of its clinicoradiologic characteristics and pa-
thogenic mechanisms.
Herein we review recent studies in which modern methods 
of stroke evaluation have been applied to identify the character-
istics of stroke in cancer patients, such as biomarkers, multimod-
al magnetic resonance imaging (MRI), and embolism monitor-
ing using transcranial Doppler ultrasound (TCD). This review 
covers the epidemiology, mechanisms, and acute and preven-
tive treatments for cancer-related stroke.
Subtypes of Stroke and Cancer  
Differ between Patients with and 
without Conventional Stroke 
Mechanisms
The controversies regarding the characteristics of stroke in pa-
tients with cancer may be due to the involvement of both can-
cer-unrelated and cancer-related mechanisms in the develop-
ment of stroke in cancer patients (Table 1). In cancer patients with-
out conventional stroke mechanisms (CSM; e.g., atherosclerosis, 
cardioembolism, or lacunar), a cancer-specific mechanism can 
be considered as the main cause of stroke. We recently prospec-
tively studied 161 patients registered from 6 centers in South 
Korea with active cancer who experienced acute ischemic 
stroke.
5 Stroke outside CSM occurred in a large proportion of 
cancer patients: CSM were absent in -40% of stroke patients 
with cancer, and occurred with a higher frequency of crypto-
genic mechanisms than in stroke patients without cancer (18%). 
Interestingly, tumor-specific mechanisms were unlikely to play 
a role in the development of stroke among patients exhibiting 
CSM, given that the distribution of stroke subtype among can-
cer patients with CSM was similar to that in stroke patients with-
out cancer (Fig. 1).
The characteristics of cancer, including the type (primary can-
cer and pathologic type) and extent of cancer and the time in-
terval from diagnosis of cancer and stroke, may be important in 
the development of stroke in patients with cancer. Patients with 
stroke had different primary cancers; lung cancer being the most 
common, followed by gastric and colorectal cancer (Table 2). 
When we compared this to the data from the Samsung Cancer 
Center, the proportion of primary cancer types did not differ be-
tween patients with and without stroke. The one exception was 
lung cancer, which was significantly more prevalent among 
stroke patients than among those without stroke. Among the pa-
thologic type of lung cancer, adenocarcinoma was significantly 
more prevalent in patients without CSM than in those with CSM 
or those without stroke; about 70% of patients without CSM had 
adenocarcinoma, whereas about 70% of patients with cancer-un-
Table 1. Mechanisms underlying stroke in patients with cancer
Cancer-unrelated mechanisms
Conventional stroke mechanisms
Atherosclerosis, cardioembolic, lacunar, etc.
Cancer-related mechanisms
Coagulopathy by 
Tumor cell (especially adenocarcinoma)-derived cytokines or microparticles
Tissue factor and cancer procoagulants
Cytokines such as tumor necrosis factor-α, interleukins
Intravascular coagulation or nonbacterial thrombotic endocarditis
Tumor occlusion
Tumor embolism (lung or cardiac), intravascular lymphoma
Direct tumor-related (metastasis or central nervous system tumor)
Vessel compression or infiltration
Treatment-related mechanisms
Chemotherapy causing coagulopathy, such as cisplatin, methotrexate, l-asparaginase, bevacizumab
Radiation or surgery causing vascular stenosis
Medical comorbidities, such as fungal infection or infective endocarditisBang OY et al.
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related stroke or those without stroke had nonadenocarcinoma 
types. Moreover, metastasis at the time of stroke was more prev-
alent among patients without CSM than among those with CSM.
5 
These findings suggest that although occult tumor may cause 
coagulopathy and thromboembolism, patients with certain types 
of advanced-stage cancer are prone to cancer-related stroke.
Characteristics of Cancer-Related 
Stroke
The clinical and radiological features and laboratory findings 
may help to identify patients with cancer-related stroke mech-
anisms. There have been conflicting reports concerning wheth-
er or not risk factors in cancer patients (vs. noncancer patients) 
differ.
6-9 However, in previous studies, CSM were pooled with 
cancer-related mechanisms. In our study, patients with CSM 
were older and were more likely to have vascular risk factors 
than were patients without CSM.
5
It has been reported that the pattern of the lesion identified 
on diffusion-weighted imaging (DWI) is correlated with the pa-
thogenic mechanism underlying the stroke as well as the out-
come after stroke.
10,11 The infarct pattern in cancer patients with 
stroke is seldom reported. DWI patterns of multiple lesions in-
volving multiple arterial territories were more frequently ob-
served in patients without CSM, whereas single/multiple lesions 
involving one arterial territory were observed more frequently 
in patients with CSM (Fig. 2).
5 Recent studies have demonstrat-
ed that concealed cancer should be considered in patients who 
exhibit multiple infarcts on DWI.
12
Laboratory findings suggesting coagulopathy may also pre-
dict possible cancer-specific stroke mechanisms. The level of D-
dimer, a plasmin-derived degradation product of cross-linked fi-
brin, is a direct measure of activated coagulation, and has been 
used in many previous studies as a measure of hypercoagulabil-
ity.
4,13 Most patients without CSM had elevated D-dimer levels, 
and the levels were higher in patients with multiple embolic 
strokes than in patients with a single infarct or multiple infarcts 
within one vascular territory.
5 Our results and those of others sug-
gest that there is a strong correlation between D-dimer level and 
the tumor burden and stage.
5,14-17
Thus, the aforementioned parameters may predict possible 
cancer-related stroke mechanisms. Most patients with both DWI 
patterns of multiple lesions involving multiple arterial territo-
ries (pattern 3 or 4) and D-dimer levels of >1.11 μg/mL had can-
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Stroke mechanisms
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Stroke patients without cancer (data from the Samsung Stroke Center)
Fig. 1. Stroke subtypes in patients with 
vs. without cancer (data from the Sam-
sung Stroke Center). Figure modified from 
Kim et al.
5 CSM: conventional stroke mech-
anisms.
Table 2. Cancer types in patients with vs. without stroke
Cancer type
Stroke patients with cancer, n (%)
Cancer patients without stroke, n (%)*
Cryptogenic group CSM group Total
Gastric 12 (18.8%) 13 (13.4%) 25 (15.5%) 1,764 (15.9%)
Colorectal 5 (7.8%) 18 (18.6%) 23 (14.3%) 1,229 (11%)0.
Breast 1 (1.6%) 1 (1.0%) 2 (1.2%) 999 (9%)0
Hepatic 4 (6.3%) 9 (9.3%) 13 (8.1%)0 1,274 (11.5%)
Lung 21 (32.8%) 26 (26.8%) 47 (29.2%)  1,276 (11.5%)†
  Adenocarcinoma  15 (71.4%)†   6 (23.1%) 21 (44.7%)    421 (33.0%)
Cervical 0 (0%)0. 2 (2.1%) 2 (1.2%) 332 (3%)0
Other 21 (32.8%) 28 (28.9%) 49 (30.4%) 4,228 (38.1%)
Total 64 97 161 11,097
*Data from the Samsung Cancer Center, †p<0.001, stroke patients with cancer vs. cancer patients without stroke.
CSM: conventional stroke mechanisms.Cancer and Stroke
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cer-specific stroke (31 of 36 patients, 86.1%), whereas CSM were 
found in most patients with none of these findings (36 of 40 pa-
tients, 90%). After adjusting for other factors, the DWI lesion 
pattern of multiple vascular territories and D-dimer levels of >1.11 
μg/dL were independently associated with the possibility of 
cancer-related stroke mechanisms.
5 The area under the receiver 
operating characteristic curve for this stroke mechanism accord-
ing to the presence of DWI pattern of multiple vascular territo-
ries or D-dimer levels of >1.11 μg/mL was 0.781 (95% confi-
dence interval, 0.715-0.838).
Embolism Caused by Coagulopathy 
as the Main Mechanism of Stroke
A recent study that monitored embolic signals using TCD show-
ed that embolisms caused by coagulopathy could be the main 
pathomechanism underlying cancer-related stroke.
14 A routine 
TCD study to detect embolism cannot generally be recommend-
ed for routine diagnostics in stroke patients due to its low sen-
sitivity; in one study, embolic signals were detected in only 5.7% 
of unselected stroke patients.
18 However, the frequency of em-
bolic signals on TCD suggestive of embolic origin is very high 
in cancer patients with acute ischemic stroke.
14 An embolic sig-
nal was observed in almost 50% of cancer patients with acute 
ischemic stroke, but more frequently in patients without CSM 
(58%) than in those with CSM (33%)(Fig. 3A). Moreover, the 
number of embolic signals was correlated with the D-dimer lev-
els in patients without CSM but not in those with CSM (Fig. 
3C and D), and the use of anticoagulation dramatically de-
creased the D-dimer levels (supplementary Fig. 1).
14 The detec-
tion of an embolic signal by TCD may provide clues regarding 
the cancer-specific mechanism related to hypercoagulopathy, and 
may be used to monitor the effect of treatment in the acute stroke 
period.
The source of the embolism causing multiple embolic strokes 
in cancer patients is unknown. Nonbacterial thrombotic endo-
carditis (NBTE) involves the deposition of small sterile vege-
tations on the heart valve leaflets and is most commonly found 
in patients with cancer. DWI has revealed NBTE patterns, with 
all patients with NBTE exhibiting multiple widely distributed 
large and small strokes (pattern 4).
19 In our data, more than 40% 
of patients without CSM showed disseminated small lesions 
(pattern 3) on DWI, and transesophageal echocardiography did 
not usually reveal vegetations. These findings suggest that in-
travascular clot formation is one of the main sources of such 
embolisms.
Thrombosis as a complication of cancer was first proposed 
by Trousseau in 1865, but the precise mechanisms underlying 
coagulopathy in cancer patients remain to be established. It has 
been suggested that substances in tumor cells, such as cysteine 
proteases, tissue factor, and sialic acid moieties of mucin, ex-
hibit procoagulant activity, resulting in the activation of factors 
X and VII.
2,20 In addition, aggressive antitumor therapy may also 
increase the risk of thrombosis.
21
Membrane-derived microvesicles are reported to be function-
al in that they support the tumor environment, such as neovas-
Conventional stroke 
mechanism DWI lesion pattern Examples
D-dimer Present Absent
Pattern 1
  Single lesion
1.2±1.9 26 (27%) 5 (8%)
Pattern 2
  Multiple lesions 
    in a single arterial 
    territory
2.8±5.6 51 (53%) 14 (22%)
Pattern 3
  Multiple small lesions 
    involving multiple 
    arterial territories
11.7±14.3 11 (11%) 26 (41%)
Pattern 4
  Multiple small 
    and large disseminated  
    lesions
10.3±20.0 9 (9%) 19 (30%)
Fig. 2. Diffusion-weighted imaging (DWI) 
lesion patterns in patients with and with-
out conventional stroke mechanisms.Bang OY et al.
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cularization in cancer patients.
22,23 Tissue-factor-bearing micro-
vesicles were associated with the activation of coagulation in 
patients with colorectal cancer.
24-26 The levels of tissue-factor-
positive microvesicles were elevated in cancer patients and were 
correlated with D-dimer levels, suggesting that tissue-factor-bear-
ing microvesicles are involved in the activation of coagulation 
in cancer patients.
25 Tissue factor is not only the primary cellu-
lar initiator of blood coagulation, it is also a modulator of angio-
genesis and metastasis in cancer.
24 Further studies are needed on 
preventive strategies targeting tissue factors to prevent coagu-
lopathy and to control the tumor environment.
Acute and Preventive Treatment 
Strategies for Cancer-Related Stroke
Stroke patients with CSM should be treated according to the 
stroke subtype (e.g., atherosclerotic or lacunar), because the mech-
anisms underlying the stroke in these patients are unlikely to dif-
fer from those of stroke patients without cancer.
5 However, the 
optimal acute treatment and preventive strategies for cancer-re-
lated stroke remain to be established.
In the setting of acute ischemic stroke, recanalization thera-
py remains the principal therapeutic approach. The use of throm-
bolytics within the therapeutic time window is not contraindi-
cated in cancer patients under the current guidelines for acute 
stroke therapy. However, the response to thrombolysis may dif-
fer between stroke patients with and without cancer. Multimodal 
MRI, including DWI and perfusion-weighted imaging, may help 
in the selection of patients for recanalization therapy.
27 Patients 
who exhibited a target mismatch pattern (substantial penumbra 
and small core) had a favorable clinical response to recanaliza-
tion therapy.
28 However, the target mismatch profile is seldom 
A  
C   D  
B  
50
50 50
100
40 80
30
10 10
60
20 40
10
1 1
20
0
0 0
0
Cryptogenic
0.0 0.0 20.0 10.0 40.0 20.0 60.0
D-dimer level (μg/mL) D-dimer level (μg/mL)
80.0 30.0
Spearman’s correlation analysis
r=0.732            p＜0.001
Spearman’s correlation analysis
r=0.152             p=0.375
100.0 40.0
Cryptogenic Other Other Large-artery
atherosclerosis
Large-artery
atherosclerosis
Cardio-
embolism
Cardio-
embolism
Small-artery
occlusion
Small-artery
occlusion
N
u
m
b
e
r
 
o
f
 
E
S
N
u
m
b
e
r
 
o
f
 
E
S
N
u
m
b
e
r
 
o
f
 
E
S
D
-
d
i
m
e
r
 
l
e
v
e
l
s
 
(
μ
g
/
m
L
)
Fig. 3. Numbers of embolic signals (ES) on transcranial Doppler ultrasound (A) and D-dimer levels (B) for each stroke subtype. The scatterplot 
shows the correlation between the number of ES and D-dimer levels by subtype of ischemic stroke. (C) Patients without conventional stroke 
mechanisms (CSM) and (D) those with CSM. Figure modified from Seok et al.
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observed in cancer-related stroke. Patients with cancer-related 
stroke often exhibit normal perfusion-weighted imaging and an-
giographic findings, even in the presence of multiple infarcts and 
severe neurological deficits. Patients with higher D-dimer lev-
els are less likely to exhibit the target mismatch pattern (unpub-
lished data). Moreover, patients with cancer-related stroke of-
ten present with progressive neurological deficits over hours 
to days (or even weeks) rather than sudden catastrophic events 
with initial maximum deficits at onset (a representative case is 
shown in supplementary Fig. 2). In many patients, multifocal 
thromboembolism culminates in widespread infarcts of vari-
ous sizes, producing confusion, lethargy, or dementia.
19 Thus, it is 
conceivable that patients with cancer-related stroke will often 
be ineligible for thrombolysis (outside the therapeutic time win-
dow) or unlikely to have a favorable response to thrombolysis 
(absence of penumbrae) at the time of presentation of ischemic 
symptoms.
In contrast, preventing recurrent embolism is important in 
cancer-related stroke. Considering the characteristics of the pre-
senting symptoms (i.e., encephalopathy), the ischemic zone as-
sessed by MRI (i.e., relative lack of ischemic penumbrae), and 
a higher rate of recurrent embolism in cancer-related stroke pa-
tients, strategies for stroke treatment in cancer patients should 
focus on correction of the coagulopathy using appropriate an-
ticoagulants, rather than the resolution of a target mismatch 
profile.
Standard strategies for anticoagulants to prevent recurrent em-
bolism are not yet established.
29 Intravenous (or subcutaneous) 
unfractionated heparin is the preferred treatment, but life-long 
maintenance on unfractionated heparin is not practical and may 
result in serious problems, especially hemorrhagic complica-
tions. Oral vitamin K antagonists (such as warfarin) and low-
molecular-weight heparin could be appropriate alternatives. 
Several studies have successfully substituted low-molecular-
weight heparin for unfractionated heparin in managing Trous-
seau’s syndrome. Thromboprophylaxis using heparin or low-
molecular-weight heparin is currently recommended in cancer 
patients as a prophylactic to prevent venous thromboembolism 
(deep venous thrombosis or pulmonary embolism).
30,31 There 
have been two large clinical trials of the use of low-molecular-
weight heparin to prevent thrombosis in patients with cancer.
32,33 
In patients with venous thromboembolism, low-molecular-
weight heparin was more effective than an oral anticoagulant in 
reducing the risk of recurrent thromboembolism without the risk 
of bleeding.
32 In patients with metastatic or locally advanced can-
cer who were receiving chemotherapy, the prophylactic use of 
low-molecular-weight heparin reduced the incidence of throm-
boembolic events.
33 In addition, a risk model predictive of che-
motherapy-associated venous thromboembolism has been vali-
dated based on laboratory findings and the characteristics of 
cancer.
30 However, nether direct evidence nor guidelines are 
available in stroke patients with cancer. Further studies are 
therefore needed in the field of stroke.
Conclusion
The studies presented in this review highlight the importance 
of a personalized approach in treating stroke patients with can-
cer. The current knowledge can be summarized as follows:
1) Cancer is a prothrombotic condition that often manifests 
as a stroke.
2) Stroke with a cancer-specific mechanism occurs in a large 
proportion of cancer patients. With the increase in the number 
of people living with cancer, this type of stroke could become 
one of the prevalent stroke subtypes in the future.
3) The characteristics of cancer-related stroke are very dis-
tinct from those of conventional stroke. Embolism caused by 
cancer-related coagulopathy is the main mechanism underlying 
cancer-related stroke.
4) Improving our understanding of the characteristics of stroke 
in cancer patients using modern diagnostic evaluations is essen-
tial to the correct management of these patients.
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